Sector News

Gilead poaches Bristol-Myers oncology executive to lead research biology

February 20, 2020
Life sciences

Gilead Sciences has a new head of research biology: Michael Quigley, Ph.D., an alum of MedImmune, Johnson & Johnson and the Dana-Farber Cancer Institute, who joins from Bristol-Myers Squibb.

The company also promoted Linda Higgins, Ph.D., to head of external innovation.

Quigley started at Bristol-Myers as a bench scientist working to discover new targets in immuno-oncology and then took a stint at J&J’s Janssen before returning to BMS, according to his LinkedIn profile. Most recently, Quigley was a vice president and head of the Big Pharma’s Tumor Microenvironment Modulation Thematic Research Center. He was also in charge of Bristol-Myers’ Redwood City, California, site.

In that role, he oversaw strategy for the company’s oncology discovery portfolio and business development, leading target identification and validation, and preclinical development of large- and small-molecule treatments. As SVP of research biology, Quigley will report to Gilead research chief William Lee, Ph.D., the company said in a statement.

Higgins joined Gilead in 2010 as VP of biology and led a “significant expansion” of her unit, including setting up biologics and biomarker teams as well as creating discovery groups for inflammation, oncology and immunology. Under her leadership, the biology unit pushed more than 30 compounds into development, including eight that reached market, Gilead said.

“We are very pleased to welcome Mike to Gilead and Linda to her new role, as we seek to build and scale our access to scientific innovation, both internally and externally,” Lee said in the statement. “These appointments strengthen our research discovery organization and will help position us to reach our ambitious goal of bringing 10 new transformative therapies to patients over the next 10 years.”

Quigley and Higgins’ appointments come after a turbulent period for Gilead, which saw a series of exits from its C-suite in 2018. Longtime Roche executive Daniel O’Day signed on to lead Gilead in late 2018, taking over from John Milligan the following March.

By Amirah Al Idrus

Source: Fierce Biotech

comments closed

Related News

February 4, 2023

MedTrace receives U.S. patent for diagnosing the human heart

Life sciences

The U.S. Patent and Trademark Office issued a patent to MedTrace for their method of diagnosing the human heart via 15O-water PET. The patented method is the foundation of the company’s software aQuant, currently under development. Hendrik “Hans” Harms, PhD and Senior Scientist at MedTrace, and Jens Soerensen, Professor and Clinical Advisor to MedTrace, are the originators of the method.

February 4, 2023

Roche taps insider Teresa Graham for top pharma job as setbacks prompt M&A questions

Life sciences

Teresa Graham, currently head of global product strategy for Roche pharma, will become the division’s new CEO next month, Roche said Thursday. Simultaneously, Roche is elevating Levi Garraway, chief medical officer, to the executive committee.

February 4, 2023

J&J’s pharma group quietly works through global overhaul, with layoffs expected to reach multiple countries

Life sciences

Fierce Pharma has obtained internal documents and video of a town hall meeting conducted this week describing what J&J called a “comprehensive review” of its portfolio. Moving forward, J&J plans to operate its vaccines and infectious diseases outfits as one group, the executives explained.

How can we help you?

We're easy to reach